Citizens Jmp Reiterates Market Outperform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “market outperform” rating reiterated by research analysts at Citizens Jmp in a research report issued on Tuesday,Benzinga reports. They currently have a $34.00 target price on the biopharmaceutical company’s stock. Citizens Jmp’s price target would indicate a potential upside of 30.12% from the company’s previous close.

A number of other analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Stifel Nicolaus set a $37.00 price objective on ACADIA Pharmaceuticals in a research note on Tuesday, December 16th. Piper Sandler set a $37.00 price objective on ACADIA Pharmaceuticals in a research note on Tuesday, December 16th. Royal Bank Of Canada cut their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. decreased their price target on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $31.30.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $26.13 on Tuesday. The stock has a market cap of $4.42 billion, a P/E ratio of 16.86, a PEG ratio of 6.08 and a beta of 0.66. The firm’s 50 day moving average price is $26.53 and its 200-day moving average price is $24.44. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.14 by $0.28. The business had revenue of $278.63 million during the quarter, compared to the consensus estimate of $276.52 million. ACADIA Pharmaceuticals had a net margin of 24.94% and a return on equity of 14.61%. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 EPS. As a group, equities analysts expect that ACADIA Pharmaceuticals will post 0.7 EPS for the current year.

Insider Buying and Selling

In related news, insider James Kihara sold 4,084 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $96,749.96. Following the transaction, the insider directly owned 25,058 shares of the company’s stock, valued at $593,624.02. This trade represents a 14.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director James M. Daly sold 30,000 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the completion of the transaction, the director directly owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. The trade was a 88.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 44,346 shares of company stock valued at $1,010,957 over the last three months. 28.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of ACADIA Pharmaceuticals by 113.0% in the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the period. USA Financial Formulas acquired a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $41,000. Finally, GAMMA Investing LLC increased its holdings in ACADIA Pharmaceuticals by 25.8% during the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $37 price target (about a 41.6% upside from current levels), which likely helped investor demand and supports upside expectations. HC Wainwright Reaffirms Buy
• Positive Sentiment: Zacks highlights ACADIA’s history of earnings beats and says the company is positioned to surprise again, reinforcing short-term bullish sentiment tied to fundamentals and upcoming results. Zacks: Why Acadia Is Poised To Beat
• Neutral Sentiment: Acadia says it was informed of a negative trend vote from the EMA’s CHMP on its trofinetide MAA and intends to request a re-examination if the final opinion is unfavorable — this preserves a regulatory path but adds near-term uncertainty. BusinessWire: Acadia Provides Update on Trofinetide
• Neutral Sentiment: Commentary pieces weigh whether ACAD is still attractive after the recent rebound and note the bull case may be altered by the EMA setback — useful for positioning but not new fundamental data. Yahoo: Is It Too Late To Consider ACAD?
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares), so it provides no meaningful signal about bearish positioning at this time.
• Negative Sentiment: Multiple outlets report the CHMP/EMA outcome is leaning negative for trofinetide for Rett syndrome; that regulatory risk is the primary near-term headwind and drove selling pressure. MarketWatch: Acadia Expects Negative Opinion
• Negative Sentiment: The stock reacted sharply to the EMA news, sliding in extended trading on Feb. 2 as investors weighed the regulatory setback and its commercial implications. MSN: Why Did ACAD Stock Slump 8% After-Hours?

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.